A community-led initiative to de-risk and advance Parkinson’s disease therapeutic targets

A community-led initiative to de-risk and advance Parkinson’s disease therapeutic targets

Abstract Identifying effective therapeutic targets for Parkinson’s disease (PD) is challenging, with no current disease-modifying therapies available. To address this, The Michael J. Fox Foundation for Parkinson’s Research launched the Targets to Therapies (T2T) initiative, uniting experts to priori...

Full description

Saved in:
Bibliographic Details
Main Authors: Alexandra Vaiana, Jonathan Behr, Ryan Birol, Cornelis Blauwendraat, Bradford Casey, Kushan Chowdhury, Martin Citron, Joshua Crapser, Victoria Dardov, Fiona Ducotterd, Sonya Dumanis, John Dunlop, Michelle Durborow, Brian Fiske, Jessica Golden, Jonas Hannestad, Wendy Hung, Jennifer Kemp, Robin Kleiman, Adam Knight, Andrew Koemeter-Cox, Bruce Leuchter, Bejamin A. Logsdon, Rita Marreiros, Julie E. Miller, Amanda Mitchell, Pooja Mukherjee, Grace Navarro, Matthew R. Nelson, Karoly Nikolich, Tom Otis, Nicole Polinski, Shima Rastegar-Pouyani, Alastair D. Reith, Ekemini Riley, Lee Rubin, Mina Ryten, Jessica Sadick, Tina Schwabe, Todd Sherer, Sarah Silvergleid, Andrew Singleton, Lara St. Clair, Jan Stoehr, David J. Stone, Julianna Sullivan, Nicole Tanenbaum, Elisa Tinelli, Kate Trimble, Yifei Wang, Stacie Weninger, Nicolás Wiggenhauser, Stephen Wood, Darryle Schoepp, Virginie Buggia-Prevot, Shalini Padmanabhan, Gaia Skibinski
Format: Article
Language:English
Published: Nature Portfolio 2025-06-01
Series:npj Parkinson's Disease
Online Access:https://doi.org/10.1038/s41531-025-01039-3
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Identifying effective therapeutic targets for Parkinson’s disease (PD) is challenging, with no current disease-modifying therapies available. To address this, The Michael J. Fox Foundation for Parkinson’s Research launched the Targets to Therapies (T2T) initiative, uniting experts to prioritize and validate promising targets. T2T aims to develop validation strategies, create comprehensive target data profiles, and build tools to support drug development, ultimately accelerating the discovery of new therapies for PD patients.
ISSN:2373-8057

Similar Items